Top

Published in:

01-08-2017 | Review Article

Advances in the Diagnosis and Treatment of Barrett’s Esophagus and Early Esophageal Cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium

Authors: Jon C. Gould, Mark R. Wendling, Brant K. Oeschlager, Sumeet K. Mittal, Srinadh Komanduri, Kyle A. Perry, Sean Cleary, Susan Galandiuk, Daniel J. Scott, P. Marco Fisichella, Nicholas J. Shaheen, Kelly R. Haisley, John G. Hunter

Published in: Journal of Gastrointestinal Surgery | Issue 8/2017

Abstract

Background

Patients with Barrett’s esophagus (BE) are at increased risk of developing esophageal adenocarcinoma (EAC). The incidence of EAC is rising faster than any other cancer.

Discussion

Patients with BE have a 30- to 40-fold increased risk of EAC. In the past 20 years, there have been dramatic advances in our understanding of the incidence and natural history of BE. Endoscopic treatment of BE is evolving. Even early EAC has been treated without esophagectomy and good oncologic results in the modern era.

Sharma P, Dent J, Armstrong D Bergman JJ, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GN, Vieth M. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392–9CrossRefPubMed

Bremner CG, Lynch VP, Ellis FH. Barrett’s esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970;68:209–16.PubMed

Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med 1976; 295:476–80CrossRefPubMed

Kapoor H, Agrawal DK, Mittal SK. Barrett’s Esophagus: recent insights in to pathogenesis and cellular ontogeny. Translational Research 2015; 166(1): 28–40CrossRefPubMed

American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011;140(3):1084CrossRef

Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2016;111(1):30CrossRefPubMed

Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013; 145(2):312–9CrossRefPubMedPubMedCentral

Canto MI, Anandasabapathy S, Brugge W, Falk GW, Dunbar KB, Zhang Z, Woods K, Almario JA, Schell U, Goldblum J, Maitra A, Montgomery E, Kiesslich R; Confocal Endomicroscopy for Barrett’s Esophagus or Confocal Endomicroscopy for Barrett’s Esophagus (CEBE) Trial Group. In vivo endomicroscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial. Gastrointest Endosc 2014;79(2):211–21CrossRefPubMed

Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJ, Tijssen JG, Bergman JJ. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014;311(12):1209–17CrossRefPubMed

10.

Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11(10):1245–55.CrossRefPubMed

11.

Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, Manner H, Guenter E, Huijsmans J, Vieth M, Stolte M, Ell C. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008;57(9):1200–6.CrossRefPubMed

12.

van Vilsteren FG, Pouw RE, Seewald S, Alvarez Herrero L, Sondermeijer CM, Visser M, Ten Kate FJ, Yu Kim Teng KC, Soehendra N, Rösch T, Weusten BL, Bergman JJ. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011;60 (6):765–73.CrossRefPubMed

13.

Haidry RJ, Butt MA, Dunn JM, Gupta A, Lipman G, Smart HL, Bhandari P, Smith L, Willert R, Fullarton G, Di Pietro M, Gordon C, Penman I, Barr H, Patel P, Kapoor N, Hoare J, Narayanasamy R, Ang Y, Veitch A, Ragunath K, Novelli M, Lovat LB; UK RFA Registry. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett’s oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 2015;64(8):1192–9CrossRefPubMed

14.

Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011;141(2):460–8.

15.

Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams JA, Falk GW, Ginsberg GG, Rustgi AK, Lightdale CJ, Wang TC, Fudman DI, Poneros JM, Wang KK. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145(1):79–86CrossRefPubMedPubMedCentral

16.

Phoa KN, Pouw RE, Bisschops R, Pech O, Ragunath K, Weusten BL, Schumacher B, Rembacken B, Meining A, Messmann H, Schoon EJ, Gossner L, Mannath J, Seldenrijk CA, Visser M, Lerut T, Seewald S, ten Kate FJ, Ell C, Neuhaus H, Bergman JJ. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2016;65(4):555–62CrossRefPubMed

17.

Pasricha S, Bulsiewicz WJ, Hathorn KE, Komanduri S, Muthusamy VR, Rothstein RI, Wolfsen HC, Lightdale CJ, Overholt BF, Camara DS, Dellon ES, Lyday WD, Ertan A, Chmielewski GW, Shaheen NJ. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014;12(11):1840–7CrossRefPubMedPubMedCentral

18.

Krishnamoorthi R, Singh S, Ragunathan K, A Katzka D, K Wang K, G Iyer P. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy: a systematic review and meta-analysis. Gastrointest Endosc 2016;83(6):1090–1106CrossRefPubMedPubMedCentral

19.

Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012;143(3):576–81.CrossRefPubMedPubMedCentral

20.

Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 2003;237:291–8.PubMedPubMedCentral

21.

Attwood SE, Lundell L, Hatlebakk JG, Eklund S, Junghard O, Galmiche JP, Ell C, Fiocca R, Lind T. Medical or surgical management of GERD patients with Barrett’s esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646–54CrossRefPubMed

22.

Ferraris R, Fracchia M, Foti M, Sidoli L, Taraglio S, Vigano’ L, Giaccone C, Rebecchi F, Meineri G, Senore C, Pera A; Gruppo Operativo Studio Precancerosi Esofagee. Barrett’s oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther 2007;25:835–40.CrossRefPubMed

23.

Shaheen NJ, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, Corbett FS, Camara DS, Rothstein RI, Overholt BF. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. J Gastrointest Surg 2013;17:21–8CrossRefPubMed

24.

Skrobic O, Simic A, Radovanovic N, Ivanović N, Micev M, Peško P. Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus. Surg Endosc 2016;30(9):3802–7CrossRefPubMed

25.

Chang EY, Morris CD, Seltman AK, O’Rourke RW, Chan BK, Hunter JG, Jobe BA. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 2007;246:11–21.CrossRefPubMedPubMedCentral

26.

Knight BC, Devitt PG, Watson DI, Smith LT, Jamieson GG, Thompson SK. Long-term Efficacy of Laparoscopic Antireflux Surgery on Regression of Barrett’s Esophagus Using BRAVO Wireless pH Monitoring: A Prospective Clinical Cohort Study. Ann Surg 2016 Oct 4. [Epub ahead of print]

27.

Pech O, May A, Manner H, Behrens A, Pohl J, Weferling M, Hartmann U, Manner N, Huijsmans J, Gossner L, Rabenstein T, Vieth M, Stolte M, Ell C. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146(3):652–660CrossRefPubMed

28.

Schmidt HM, Mohiuddin K, Bodnar AM, El Lakis M, Kaplan S, Irani S, Gan I, Ross A, Low DE. Multidisciplinary treatment of T1a adenocarcinoma in Barrett’s esophagus: contemporary comparison of endoscopic and surgical treatment in physiologically fit patients. Surg Endosc 2016; 30:3391–401.CrossRefPubMed

29.

Wani S, Drahos J, Cook MB, Rastogi A, Bansal A, Yen R, Sharma P, Das A. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc 2014; 79:224–232.CrossRefPubMed

30.

Huntington JT, Walker JP, Meara MP, Hazey JW, Melvin WS, Perry KA. Endoscopic mucosal resection for staging and treatment of early esophageal carcinoma: a single institution experience. Surg Endosc 2015; 29:2121–2125.CrossRefPubMed

31.

Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc 2013;77(2):190–9CrossRefPubMed

32.

Molena D, Schlottmann F, Boys JA, Blackmon SH, Dickinson KJ, Dunst CM, Hofstetter WL, Lada MJ, Louie BE, Mungo B, Watson TJ, DeMeester SR. Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases. J Gastrointest Surg 2017;21(1):62–67CrossRefPubMed

33.

Manner H, Pech O, Heldmann Y, May A, Pohl J, Behrens A, Gossner L, Stolte M, Vieth M, Ell C. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013; 11:630–5.CrossRefPubMed

34.

Luna RA, Gilbert E, Hunter JG. High-grade dysplasia and intramucosal adenocarcinoma in Barrett’s esophagus: the role of esophagectomy in the era of endoscopic eradication therapy. Curr Opin Gastroenterol. 2012 Jul;28(4):362–9

35.

Title: Advances in the Diagnosis and Treatment of Barrett’s Esophagus and Early Esophageal Cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium
Authors: Jon C. Gould
Mark R. Wendling
Brant K. Oeschlager
Sumeet K. Mittal
Srinadh Komanduri
Kyle A. Perry
Sean Cleary
Susan Galandiuk
Daniel J. Scott
P. Marco Fisichella
Nicholas J. Shaheen
Kelly R. Haisley
John G. Hunter
Publication date: 01-08-2017
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 8/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-017-3390-5

At a glance: The STEP trials

Springer Medicine

Advances in the Diagnosis and Treatment of Barrett’s Esophagus and Early Esophageal Cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium

Abstract

Background

Discussion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Discussion

Please log in to get access to this content

Other articles of this Issue 8/2017

Differences in Effectiveness and Use of Robotic Surgery in Patients Undergoing Minimally Invasive Colectomy

Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival

Long-Term Trends in Hematological and Nutritional Status After Gastrectomy for Gastric Cancer

Domino Reconstruction of the Portal Vein Using the External Iliac Vein and an ePTFE Graft in Pancreatic Surgery

Current Concepts in Treatment of Barrett’s Esophagus With and Without Dysplasia

Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time